Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax has experienced a notable decline in its stock price over the past week, dropping by 8.82%. This downturn comes amidst a challenging landscape for the company, as Citi ini ...

Novavax (NVAX) concluded the recent trading session at $6.41, signifying a +1.75% move from its prior day's close.

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Shares of Novavax Inc. NVAX slid 7.68% to $6.49 Tuesday, on what proved to be an all-around poor trading session for the ...

Market Domination hosts Josh Lipton and Julie Hyman go over some of the day's top trending tickers. Novavax (NVAX) stock is soaring after the company's COVID-19 vaccine was approved by the US Food and ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Federal regulators are asking Novavax NVAX2.09%increase; green up pointing triangle to complete an additional randomized clinical trial on its Covid-19 vaccine after previously delaying approval ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to grant Novavax full approval – without restrictions -- by its April 1 target ...

This was the stock's second consecutive day of losses.